GSK, Verily-backed Galvani starts trials of bioelectronic arthritis therapy
pharmaphorum
JANUARY 27, 2022
Lab studies have suggested that this type of stimulation can alter immune cells made in the spleen switching them from a pro-inflammation to an anti-inflammation state. Galvani is using its device to stimulate the splenic nerve, which sends signals to the spleen.
Let's personalize your content